SURMOUNT-1—Results of The First Phase 3 Obesity Trial with The Novel GIP/GLP-1 Receptor Agonist Tirzepatide
In this medfyle
Unprecedented weight loss with tirzepatide in obesity.
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
Expert commentary
About this Medfyle
This is a highlights summary of an oral session given at the ADA 2022 - 82nd Scientific Sessions and presented by:
Juan Pablo Frías, MD
Velocity Clinical Research
Los Angeles, CA, USA
Carel Le Roux, FRCP, PHD
University College Dublin
Dublin, Ireland
Sean Warton, MD, PHARMD
Wharton Medical Clinic
Toronto, ON, Canada
Ania Jastreboff, MD, PHD
Yale University School of Medicine
New Haven, CT, USA
Sriram Machineni, MD
University of North Carolina School of Medicine
Chapel Hill, NC, USA
Louis Aronne, MD
Weill Cornell Medicine
New York, NY, USA
The content is produced by Infomedica, the official reporting partner of ADA 2022.
The presenting authors of the original session had no part in the creation of this conference highlights summary.
In addition, an expert commentary on the topic has been provided by:
Ildiko Lingvay, MD, MPH, MSCS
Professor of Medicine
Department of Internal Medicine, Division of Endocrinology
Department of Population and Data Sciences
University of Texas Southwestern Medical Center, Dallas, TX, USA
